TNF blocker to be trialled as COVID-19 treatment
The Oxford University trial will take place in aged-care facilities in the UK
The UK’s University of Oxford has announced that it will be leading a trial to determine whether one of the world’s top-selling prescription medicines, adalimumab, is an effective treatment for COVID-19.
Recent studies have shown that patients with COVID-19 already taking anti-TNF drugs — such as adalimumab, for inflammatory bowel disease and inflammatory arthritis — are less likely to be admitted to hospital, the university said in a statement.
